Cargando…
Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment
As SARS-CoV-2 continues to evolve and spread with the emergence of new variants, interest in small molecules with broad-spectrum antiviral activity has grown. One such molecule, Molnupiravir (MOV; other names: MK-4482, EIDD-2801), a ribonucleoside analogue, has emerged as an effective SARS-CoV-2 tre...
Autor principal: | Githaka, John Maringa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950025/ https://www.ncbi.nlm.nih.gov/pubmed/35342288 http://dx.doi.org/10.1177/11779322221085077 |
Ejemplares similares
-
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
por: Kabinger, Florian, et al.
Publicado: (2021) -
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021) -
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
por: Gordon, Calvin J., et al.
Publicado: (2021) -
Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
por: De Vito, Andrea, et al.
Publicado: (2022) -
Robust inflammatory breast cancer gene signature using nonparametric random forest analysis
por: Zare, Alaa, et al.
Publicado: (2021)